格隆汇2月10日丨金冠电气(688517.SH)公布，近日，南方电网公司2025年主网线路材料第二批框架招标 项目中标候选人公示，公司中标35kV-220kV、500kV线路避雷器产品共2个标包，合计中标金额约 2,886.91万元。公司所披露的中标项目仅为中标金额2,000万元（含）以上项目。本次中标金额约占公司 2024年营业收入的3.88%，中标合同的履行将对公司未来经营业绩产生积极的影响。 ...

Core Viewpoint - XuanTai Pharmaceutical (688247.SH) has participated in the national centralized procurement for the continuation of products from the first to eighth batches, with its product, ursodeoxycholic acid capsules, being proposed for selection in the continuation procurement process [1] Group 1: Procurement Participation - The company has submitted an application for the continuation procurement of products whose agreements have expired, as announced by the continuation procurement office on February 10, 2026 [1] - The proposed selection of the company's product indicates a potential for increased sales and market share [1] Group 2: Impact on Business - If the company signs procurement contracts and implements them, it will likely enhance the sales scale and brand influence, positively affecting future operational performance [1]

Core Viewpoint - Tianfu Communication is expected to achieve a net profit attributable to shareholders of 1.88-2.15 billion yuan in 2025, representing a year-on-year growth of 40.0%-60.0% [1] Financial Performance - The company's net profit for Q4 2025 is projected to be 550 million yuan, reflecting a year-on-year increase of 49.9% but a quarter-on-quarter decrease of 2.8% [1] - Earnings per share (EPS) estimates for 2026, 2027, and 2028 are 2.58, 4.87, and 7.18 yuan respectively, with corresponding price-to-earnings (PE) ratios of 115.4, 61.2, and 41.5 based on the closing price on February 9 [1] Market Dynamics - The growth in performance is attributed to the stable increase in global demand for high-speed optical devices, alongside the company's ongoing efforts in smart manufacturing to reduce costs and improve efficiency [1] - Material bottlenecks are gradually easing, and the 1.6T optical engine is expected to see increased production [1] Competitive Position - The company has become an important player in the supply chain for NVIDIA's CPO through core passive component customization and high-efficiency coupling processes [1] - Tianfu Communication possesses manufacturing capabilities in FAU, optical engine packaging, and ELS modules, which are expected to enhance unit value [1] Future Outlook - Strong demand for 1.6T optical modules driven by capital expenditures in North America is anticipated to benefit major clients in 2026, with potential revenue growth from Scaleout and Scaleup CPO/NPO expected to materialize after 2027 [1]

格隆汇2月10日｜德银分析师指出，软件及科技行业对投机级信贷市场构成历来最重大的集中风险之 一。软件及科技行业在投机级信贷市场中的规模分别达5970亿美元及6810亿美元，占整体比重约14%及 16%。投机级债务涵盖高收益债券、杠杆贷款及美国私募信贷。分析师指出，相关规模属相当可观的未 偿还债务，一旦软件行业违约情况上升，或会拖累整体市场情绪，其潜在影响可与2016年能源行业危机 相提并论。 ...

欣灵电气(301388.SZ)今日盘中一度跌4.5%至34.38元。欣灵电气公布，董事兼总经理张彭春先生计划自本公告披露之日起十五个交易日后的3个月内以集中竞 价方式或大宗交易方式减持本公司股份不超过1.28%。(格隆汇) ...

国盛证券研报指出，汇嘉时代是新疆零售龙头，创新转型价值重估。公司的核心竞争优势在于其密集的 门店网络、深入的本土市场洞察以及多业态协同效应。这些优势使其在新疆地区形成了显著的规模效应 和品牌壁垒。公司积极推动超市调改和购物中心业态升级，创新性地探索"低空经济+消费"新场景，有 望打开第二增长曲线。首次覆盖给予"买入"评级。 ...

东吴证券研报指出，欣旺达与威睿诉讼和解，港股上市推进顺利，动储业务高增长。测算25年欣旺达动 力计提费用12.5-20亿元，相关计提处理非常充分，不会影响26年及之后业绩，本次和解避免陷入长期 的价格战和诉讼战，同时消除对未来港股上市、海外扩张、新客户导入和银行合作等多方面的不确定 性，集中全部精力回归经营基本面。公司26年动力毛利率目标15%，同增2pct，储能目标10-12%，同增 2-3pct，海外客户占比提升（由30%提升至40-50%），并通过技术创新、规模效应、良率提升覆盖未传 导的成本，全年动力扭亏目标不变。由于诉讼事件影响25年盈利、但26、27年公司动储业务出货强劲， 预计25-27年归母净利润14.1/30.3/41.2亿元（原预测值为20.5/30.0/41.1亿元），同比-4%/+115%/+36%， 对应PE为32x/15x/11x，给予26年25x估值，对应目标价41元，维持"买入"评级。 ...

Core Viewpoint - The company, Conch New Materials (000619.SZ), primarily engages in the research, production, and sales of plastic profiles, aluminum profiles, doors and windows, SCR denitration catalysts, and high molecular rollers. The company has not had any contact with Elon Musk's team, and its products are not utilized in the aerospace sector [1] Group 1 - The company specializes in various products including plastic profiles and aluminum profiles [1] - The company has confirmed no engagement with Elon Musk's team [1] - The company's products are not applied in the aerospace industry [1]

Core Viewpoint - Shuangle Co., Ltd. has successfully achieved mass production of Phthalocyanine Blue 15:6, which can be applied in high-end inks and coatings, with ongoing research for its use in display panels [1] Group 1 - The company has confirmed that Phthalocyanine Blue 15:6 is now in mass production [1] - Applications for the new product include high-end inks and high-end coatings [1] - Research and development for the application of Phthalocyanine Blue 15:6 in display panels is currently underway [1] Group 2 - The company has made adjustments to its high-performance production line for pigment purple, which can be utilized in the research and production of Phthalocyanine Blue 15:6 [1] - The production quantity of Phthalocyanine Blue 15:6 will depend on market demand [1]

港股通创新药ETF跟踪中证港股通创新药指数，指数编制方式更科学合理，成分股涵盖如百济神州、信达生物和药明生物等龙头企业。 港股通创新药ETF易方达是目前市场上唯一跟踪恒生港股通创新药指数的产品，该指数在编制方案中明确剔除了CXO公司，聚焦创新药产业核心企业，权重 股包括百济神州、信达生物、药明生物、康方生物等龙头公司，为投资者布局港股前沿创新药企提供了便捷工具。 港股创新药上涨，石药集团、药明生物、信达生物涨超5%，带动港股通创新药ETF嘉实、港股通创新药ETF万家、港股创新药50ETF、港股通创新药ETF鹏 华、港股创新药ETF、恒生生物科技ETF南方、港股通创新药ETF、港股创新药ETF、港股通创新药ETF南方、港股通创新药ETF工银、港股通创新药ETF、 恒生生物科技ETF易方达、 港股通医疗ETF富国上涨。 | 证券代码 | 证券简称 | 当日涨幅% | 年内涨幅 | 管理 | | --- | --- | --- | --- | --- | | 520970.SH | 港股通创新药ETF嘉实 | 3.27% | 11.03% | 嘉委 | | 520700.SH | 港股通创新药ETF万家 | 3.1 ...